home / stock / rlmd / rlmd news

RLMD News and Press, Relmada Therapeutics Inc. From 09/20/23

Stock Information
Company Name: Relmada Therapeutics Inc.
Stock Symbol: RLMD
Market: OTC
Website: relmada.com
Menu
RLMD RLMD Quote RLMD Short RLMD News RLMD Articles RLMD Message Board
Get RLMD Alerts

News, Short Squeeze, Breakout and More Instantly...
RLMD - BZUN, CMPS and QSI are among after hour movers

2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si  ( QSI ) +5% . Losers: Vahanna Tech ...
RLMD - Relmada jumps after long-term Phase 3 data for anti-depressant

2023-09-20 09:30:02 ET More on Relmada Seeking Alpha’s Quant Rating on Relmada Therapeutics Historical earnings data for Relmada Therapeutics Financial information for Relmada Therapeutics Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhan...

RLMD - Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder PR Newswire Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvemen...

RLMD - Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout

2023-09-01 18:53:42 ET Summary Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim analysis could result in an early stoppage, it isn't a guarantee but could enhance the run up effect as ...
RLMD - Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire CORAL GABLES, Fla. , Aug. 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage...

RLMD - Eton, Semler top healthcare gainers; Cano, Kezar among losers

2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...

RLMD - Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Call Transcript

2023-08-08 21:46:11 ET Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Conference Call August 08, 2023, 04:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Cedric O'Gorman - Chief Medical Officer Maged Shenouda - CFO ...
RLMD - Relmada Therapeutics GAAP EPS of -$0.84 beats by $0.06

2023-08-08 16:44:44 ET Relmada Therapeutics press release ( NASDAQ: RLMD ): Q2 GAAP EPS of -$0.84 beats by $0.06 . As of June 30, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $118.5 million, compared to cash, cash equivalent...

RLMD - Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results PR Newswire CORAL GABLES, Fla. , Aug. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the...

RLMD - Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023

Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 PR Newswire CORAL GABLES, Fla. , Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company...
Previous 10 Next 10